Independent Consultant, Nairobi, Kenya.
Trop Med Int Health. 2011 Jan;16(1):84-96. doi: 10.1111/j.1365-3156.2010.02667.x. Epub 2010 Nov 2.
To identify where vouchers have been used for reproductive health (RH) services, to what extent RH voucher programmes have been evaluated, and whether the programmes have been effective.
A systematic search of the peer review and grey literature was conducted to identify RH voucher programmes and evaluation findings. Experts were consulted to verify RH voucher programme information and identify further programmes and studies not found in the literature search. Studies were examined for outcomes regarding targeting, costs, knowledge, utilization, quality, and population health impact. Included studies used cross-sectional, before-and-after and quasi-experimental designs.
Thirteen RH voucher programmes fitting established criteria were identified. RH voucher programmes were located in Bangladesh, Cambodia, China, Kenya (2), Korea, India, Indonesia, Nicaragua (3), Taiwan, and Uganda. Among RH voucher programmes, 7 were quantitatively evaluated in 15 studies. All evaluations reported some positive findings, indicating that RH voucher programmes increased utilization of RH services, improved quality of care, and improved population health outcomes.
The potential for RH voucher programmes appears positive; however, more research is needed to examine programme effectiveness using strong study designs. In particular, it is important to see stronger evidence on cost-effectiveness and population health impacts, where the findings can best direct governments and external funders.
确定代金券在生殖健康(RH)服务中的使用情况,评估 RH 代金券计划的程度,以及这些计划是否有效。
系统检索同行评议和灰色文献,以确定 RH 代金券计划和评估结果。咨询专家以验证 RH 代金券计划信息,并确定文献检索中未发现的其他计划和研究。研究考察了针对目标人群、成本、知识、利用、质量和人口健康影响的结果。纳入的研究采用了横断面、前后对照和准实验设计。
确定了符合既定标准的 13 个 RH 代金券计划。RH 代金券计划位于孟加拉国、柬埔寨、中国、肯尼亚(2 个)、韩国、印度、印度尼西亚、尼加拉瓜(3 个)、台湾和乌干达。在 RH 代金券计划中,有 7 个在 15 项研究中进行了定量评估。所有评估报告都有一些积极的发现,表明 RH 代金券计划增加了 RH 服务的利用,改善了护理质量,并改善了人口健康结果。
RH 代金券计划的潜力似乎是积极的;然而,需要更多的研究使用强有力的研究设计来检验计划的有效性。特别是,重要的是要看到关于成本效益和人口健康影响的更强有力的证据,这些证据可以最好地指导政府和外部资助者。